Inhibrx Biosciences CEO buys 5,895 shares after INBRX-106 trial results
AIサマリー
Lappe Mark purchased Inhibrx Biosciences shares after positive INBRX-106 trial results.
The CEO bought 5,895 shares at $99.29 each.
INBRX-106 combined with Keytruda produced a 48.3% tumor response rate.
Inhibrx Biosciences CEO Lappe Mark purchased 5,895 shares at $99.29 each after positive Phase 2 results for INBRX-106 combined with Keytruda. The trial recorded a 48.3% tumor response rate, described as nearly double the rate for Keytruda alone.